Christine Duncan, MD, Medical Director of Clinical Research and Clinical Development, Gene Therapy Program, Boston Children's Hospital

Med school in Chicago; Internship and Residency at Boston Children's Hospital; Pediatric
Hematology/Oncology Fellowship at DFCI; just celebrated being at the Farber for 20 years.
· Director of Clinical Research and Development, Dana-Farber/Boston Children's Cancer
and Blood Disorders Center.
· Research and clinical focus on cellular therapies for rare pediatric diseases- especially
neuro-metabolic disease and brain tumors.
· Clinical leader in partnership with local biotech company (bluebird bio) and MGH in the
research that lead to the first FDA approved therapy for children with cerebral
adrenoleukodystrophy (ALD) in the world. Cerebral ALD is a progressive neurologically
devastating disease that affects boys and ultimately leads to their deaths if not treated early.
· Leader in multiple international pediatric stem cell transplant groups.
· On the personal side: mom of three young boys, advocate for Foster Care and Adoption
from Foster Care; from Wisconsin - Green Bay Packers Fan, but love the Red Sox.
· Associate Professor of Pediatrics at Harvard Medical School; Senior Physician at DFCI.